Sonnet BioTherapeutics SONN 深 沪
等待开盘 08-30 09:30:00 美东时间
3.25
-0.130
-3.85%
华盛通- 最 高3.44
- 今 开3.29
- 成交量 33.64万股
- 最 低 3.16
- 昨 收 3.38
- 总市值 1028.89万
- 52周最高 19.30
- 市盈率 静 --
- 换手率 10.62%
- 52周最低 1.08
- 委 比 55.34%
- 总股本 316.58万
- 历史最高 329609.28
- 量 比 0.94
- 振 幅 8.28%
- 历史最低 1.08
- 每 手 1
- 风险率 3.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sonnet BioTherapeutics Q3 EPS $(0.95) Misses $(0.49) Estimate
Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.49) by 93.88 percent. This is a 83.04 percent increase over losses of $(5.60) per
08-14 15:41
Sonnet Releases Virtual Investor "What This Means" Segment
Sonnet BioTherapeutics announced the expansion of its SB221 clinical trial for platinum-resistant ovarian cancer (PROC). The expansion group, using the highest maintenance dose (E6 dose of 1200 ng/kg), has completed enrollment. Two out of three patients in the E6 dose escalation cohort showed partial responses, allowing further safety study in a larger population. Preliminary efficacy results are expected later this year. An E7 cohort with a main...
08-11 13:15
Sonnet Biotherapeutics Announces Expansion Of Its Phase 1b/2a Clinical Study Evaluating The Combination Of SON-1010 With Genentech's Atezolizumab In Patients With Platinum-Resistant Ovarian Cancer
Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221)Topline safety, cytokine, and
08-04 20:43
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
Sonnet BioTherapeutics announced the expansion of its Phase 1b/2a SB221 study for platinum-resistant ovarian cancer (PROC) with its lead product, SON-1010 (IL12-FHAB), in combination with atezolizumab. The study has completed enrollment at the highest maintenance dose (E6 dose of 1200 ng/kg), with two out of three patients showing partial responses. A new E7 cohort has been added to evaluate a 25% higher dose, and top-line data are expected in la...
08-04 12:40
IOSG：加密货币储备经济模型大解构，微策略可复制吗？
（来源：吴说） 作者：Mario Chow @IOSG 原文链接：https://mp.weixin.qq.com/s/BaVW7IWSCFaqXdRIltr...
08-02 23:17
Sonnet BioTherapeutics Appoints Interim CEO Raghu Rao
The latest update is out from Sonnet BioTherapeutics Holdings ( ($SONN) ). On J...
08-02 05:17
Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?
Sonnet to merge with crypto-backed firm, forming Hyperliquid Strategies with $888 million in assets, plus HYPE blockchain tokens.
07-14 23:30
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 239.4% to $17.55 dur...
07-14 20:08
Market-Moving News for July 14th
SONN: 300% | Sonnet Biotherapeutics Announces A Business Combination With Rorschach, A Newly-formed Entity Formed By Atlas Merchant Capital, An Affiliate Of Paradigm Operations, And Additional Sponsors, To Build A
07-14 19:18
Sonnet Biotherapeutics Announces A Business Combination With Rorschach, A Newly-formed Entity Formed By Atlas Merchant Capital, An Affiliate Of Paradigm Operations, And Additional Sponsors, To Build A Reserve Of HYPE, The Token Of The Hyperliquid Layer-1 Blockchain
At the closing of the Business Combination, the newly-created entity is to be named Hyperliquid Strategies Inc ("HSI"), which is expected to hold approximately 12.6 million HYPE tokens, representing $583 million in value
07-14 18:03
